Pancreatic Cancer Research

ResearcherNagoya UniversityActive in the last 2 years

Masamichi Hayashi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6875-2303; OpenAlex author ID A5065907694, A5086122888. Sources: OpenAlex.

Their work

Papers
45 (first author 7, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
109
Papers, trials and grants by year

2011: 2 papers · 2012: none · 2013: none · 2014: none · 2015: none · 2016: none · 2017: 2 papers · 2018: 6 papers · 2019: 4 papers · 2020: 8 papers · 2021: 6 papers · 2022: 5 papers · 2023: 3 papers · 2024: 1 paper · 2025: 3 papers · 2026: 5 papers

Papers 45

  1. Clinical Outcomes of Gemcitabine Plus Nab-Paclitaxel-Based Chemoradiotherapy in a Multidisciplinary Treatment Strategy for Locally Advanced Pancreatic Cancer (… Co-author DOI 10.1002/ijc.70801↗
  2. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  3. High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-025-18912-3↗
  4. ASO Author Reflections: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness. Co-author DOI 10.1245/s10434-026-19112-3↗
  5. ASO Visual Abstract: High E2F7 Expression Indicates Pancreatic Cancer Aggressiveness and Downregulation of E2F7 Enhances Sensitivity to S-1. Co-author DOI 10.1245/s10434-026-19134-x↗
  6. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  7. Clinical Impact for Prognostic Index of Nodal Stations and Reconsideration of Optimal Regional Lymph Node Station in Pancreatic Cancer. Co-author DOI 10.1002/jhbp.12179↗
  8. Exploration of Lipid Mediators for Therapeutic Monitoring of Pancreatic Cancer Patients. First author DOI 10.21873/anticanres.17520↗
  9. Genome-wide microRNA Analysis Identified miR-210-3p Over-expression in Pancreatic Cancer Tissues as a Predictor of their Local Invasiveness. First author DOI 10.21873/anticanres.17297↗
  10. Predictive impacts of peritoneal washing cytology for surgical resection-intended pancreatic cancer cases: Establishment of planned staging laparoscopy criteri… Co-author DOI 10.1002/jhbp.1373↗
  11. Albumin-Globulin Ratio Indicates the Survival Outcome of Pancreatic Cancer Cases Who Underwent Preoperative Treatment and Curative Surgical Resection. Co-author DOI 10.1080/01635581.2023.2191384↗
  12. High Preoperative Serum D-dimer Predicts Unfavorable Survival Outcomes for Pancreatic Cancer Patients. First author DOI 10.21873/anticanres.16491↗
  13. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group. Co-author DOI 10.1002/jhbp.1085↗
  14. Matrix remodeling-associated protein 8 is a marker of a subset of cancer-associated fibroblasts in pancreatic cancer. Co-author DOI 10.1111/pin.13198↗
  15. Downregulation of ROBO4 in Pancreatic Cancer Serves as a Biomarker of Poor Prognosis and Indicates Increased Cell Motility and Proliferation Through Activation… First author DOI 10.1245/s10434-022-12039-5↗
  16. ASO Author Reflections: Downregulation of ROBO4 in Pancreatic Cancer Serves as a Biomarker of Poor Prognosis and Indicates Increased Cell Motility and Prolifer… First author DOI 10.1245/s10434-022-12070-6↗
  17. Comparison Between FOLFIRINOX and nal-IRI/FL as Second-line Treatment After Gemcitabine Plus Nab-paclitaxel for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.15882↗
  18. The impact of early tumor shrinkage on conversion surgery and the survival in patients with unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00595-020-02220-2↗
  19. Age-Related Differences in the Prognosis of Pancreatic Cancer According to Perioperative Systemic Therapy. Co-author DOI 10.1097/mpa.0000000000001712↗
  20. Impact of molecular surgical margin analysis on the prediction of pancreatic cancer recurrences after pancreaticoduodenectomy. First author DOI 10.1186/s13148-021-01165-8↗
  21. Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-020-08990-w↗
  22. Conversion surgery in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.21037/jgo-20-243↗
  23. A Possible Definition of Oligometastasis in Pancreatic Cancer and Associated Survival Outcomes. First author DOI 10.21873/anticanres.15189↗
  24. Phase I/II study of adding intraperitoneal paclitaxel in patients with pancreatic cancer and peritoneal metastasis. Co-author DOI 10.1002/bjs.11792↗
  25. Tumor marker recovery rather than major pathological response is a preferable prognostic factor in patients with pancreatic ductal adenocarcinoma with preopera… Co-author DOI 10.1002/jhbp.748↗
  26. Clinical impact of additional therapy for residual pancreatic cancer. Co-author DOI 10.1007/s00595-019-01900-y↗
  27. Characteristics of Lung Metastasis as an Initial Recurrence Pattern After Curative Resection of Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001559↗
  28. Novel Prognostic Implications of DUPAN-2 in the Era of Initial Systemic Therapy for Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-07981-w↗
  29. Clinical Implications of Naples Prognostic Score in Patients with Resected Pancreatic Cancer. Co-author DOI 10.1245/s10434-019-08047-7↗
  30. Exploration of Exosomal Micro RNA Biomarkers Related to Epithelial-to-Mesenchymal Transition in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.14138↗
  31. Optimal Preoperative Multidisciplinary Treatment in Borderline Resectable Pancreatic Cancer. Co-author DOI 10.3390/cancers13010036↗
  32. Effects of duration of initial treatment on postoperative complications in pancreatic cancer. Co-author DOI 10.1002/jhbp.622↗
  33. Novel implications of combined arterial resection for locally advanced pancreatic cancer in the era of newer chemo-regimens. Co-author DOI 10.1016/j.ejso.2019.05.019↗
  34. Biological and conditional factors should be included when defining criteria for resectability for patients with pancreatic cancer. Co-author DOI 10.1016/j.hpb.2019.01.012↗
  35. Phase II study of chemoradiotherapy combined with gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic ductal adenocarcinoma (NUPAT 05 … Co-author DOI 10.18999/nagjms.81.2.233↗
  36. Phase I study of chemoradiotherapy using gemcitabine plus nab-paclitaxel for unresectable locally advanced pancreatic cancer. Co-author DOI 10.1007/s00280-018-3554-3↗
  37. Clinical Implications of Lysyl Oxidase-Like Protein 2 Expression in Pancreatic Cancer. Co-author DOI 10.1038/s41598-018-28253-9↗
  38. Impact of the Controlling Nutritional Status Score on the Prognosis After Curative Resection of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001105↗
  39. Comparison of the Survival Outcomes of Pancreatic Cancer and Intraductal Papillary Mucinous Neoplasms. Co-author DOI 10.1097/mpa.0000000000001110↗
  40. Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification. Co-author DOI 10.1097/mpa.0000000000001186↗
  41. Clinical Impact of Neoadjuvant Therapy on Nutritional Status in Pancreatic Cancer. Co-author DOI 10.1245/s10434-018-6699-8↗
  42. Clinical impact of sarcopenia on prognosis in pancreatic ductal adenocarcinoma: A retrospective cohort study. Co-author DOI 10.1016/j.ijsu.2017.01.075↗
  43. Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. Co-author DOI 10.1016/j.surg.2017.04.023↗
  44. Pattern of lymph node metastasis spread in pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e3182148342↗
  45. Recurrence pattern and prognosis of pancreatic cancer after pancreatic fistula. Co-author DOI 10.1245/s10434-011-1604-8↗

Closest collaborators

The 25 strongest of 109 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Mitsuro Kanda · 31 shared papers, 2011–2026 · strength 3.84
  2. Yasuhiro Kodera · 36 shared papers, 2011–2025 · strength 3.79
  3. Tsutomu Fujii · 28 shared papers, 2011–2026 · strength 2.92
  4. Suguru Yamada · 30 shared papers, 2011–2025 · strength 2.88
  5. Fuminori Sonohara · 23 shared papers, 2018–2025 · strength 2.35
  6. Norifumi Hattori · 12 shared papers, 2018–2025 · strength 1.58
  7. Nobuhiko Nakagawa · 6 shared papers, 2020–2026 · strength 1.17
  8. Tomohisa Otsu · 6 shared papers, 2022–2026 · strength 1.14
  9. Keizo Fujita · 4 shared papers, 2024–2026 · strength 1.02
  10. Nobutake Tanaka · 7 shared papers, 2018–2023 · strength 0.93
  11. Junpei Yamaguchi · 6 shared papers, 2018–2026 · strength 0.91
  12. Yukihiro Yokoyama · 6 shared papers, 2018–2026 · strength 0.91
  13. Ryo Ashida · 3 shared papers, 2026 · strength 0.84
  14. Shinji Mii · 4 shared papers, 2022–2026 · strength 0.70
  15. Sohei Satoi · 5 shared papers, 2020–2026 · strength 0.68
  16. Masaya Suenaga · 8 shared papers, 2018–2021 · strength 0.61
  17. Satoshi Hirano · 4 shared papers, 2020–2026 · strength 0.56
  18. Masaya Yamanaka · 3 shared papers, 2021–2022 · strength 0.50
  19. Nobumasa Mizuno · 2 shared papers, 2026 · strength 0.45
  20. Motokazu Sugimoto · 2 shared papers, 2026 · strength 0.45
  21. Katsuhiko Uesaka · 2 shared papers, 2026 · strength 0.45
  22. Hirochika Toyama · 2 shared papers, 2026 · strength 0.45
  23. Atsuyuki Maeda · 2 shared papers, 2026 · strength 0.45
  24. Haruyoshi Tanaka · 2 shared papers, 2025–2026 · strength 0.44
  25. Daisuke Hashimoto · 3 shared papers, 2021–2026 · strength 0.40

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.